From MultiStem after Spinal Cord Injury …
Pre-clinical results show that Intravenous Administration of ATHX's Adult Stem Cell Therapy improves function following injury
ATHX presented new research results this morning at the Society for Neuroscience annual meeting in New Orleans, demonstrating the potential for MultiStem to treat spinal cord injury (NYSE:SCI).
The work conducted by Athersys scientists, in collaboration with scientists from Case Western Reserve University School of Medicine, and with grant support from the Ohio Third Frontier, illustrates the potential benefits of MultiStem therapy for treating SCI.
The Bottom Line: I always "love" the words … "potential benefit"…and "improves function" … in a … pre-clinical "rodent" model … of SCI. Researchers observed that intravenous administration of MultiStem cells one day after injury results in accelerated recovery, significant improvements in locomotor function and fine motor tests, and significant improvement in bladder function. The animals <not a human> treated with MultiStem showed significant and sustained improvement in gross locomotor and fine motor function compared to vehicle treated animals over the ten week evaluation period. Additionally, significant improvements in bladder function were observed in the animals treated with MultiStem shortly after the SCI.
One might say, it is an actionable release but, it seems a … meaningless one <animal models> to me and, $0.01 is dribble. A little early for an "Atta boy." But, ATHX does have a 17 M share offering coming … and the stock has been trading +$0.01 to $1.22.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.